LIXIL-FOUNDATION
The LIXIL Foundation (located in Koto-ku, Tokyo; Chairman: Yoko Ushioda), which facilitates surveys and research related to the housing and building materials industries as well as supporting the development of human resources, is pleased to announce today that the next-generation sustainable housing “INFINITE FIELD” designed by The Royal Danish Academy of Fine Arts (Denmark) has been completed on a site of Memu Meadows in Taiki-cho Hokkaido, environmental technology research facilities managed by the foundation.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161027007034/en/
INFINITE FIELD is the top prize winner in the 6th LIXIL International Student Architectural Competition sponsored by the LIXIL Foundation, aimed to seek and review next-generation sustainable housing technology and communicate that technology to the global community. The project was designed based on the theme: “Comfort and Lightness.” For the first time in its history, this year’s competition called for proposals for a light shelter that can be easily assembled and moved.
INFINITE FIELD is a structure that features a 360-degree timber platform and the design enveloped by soft, permeable membranes. From this elevated platform, which is aligned with an average snow depth in this region, users are able to enjoy the view of snowfield spreading infinitely during the winter months while the platform transforms into a place to cool off in the summer heat. It is designed to allow people to feel changes of the seasons in Taiki-cho.
The varied textile membranes invite nature in and allow the architecture in itself to move. The fabric is layered to create the space; these textiles are chosen with consideration of various environmental properties to ensure a comfortable thermal environment. Dwellers can operate these layered membranes on their own, adding or removing them to adjust their relationships with the environment while they serve as an expanded threshold.
With the completion of INFINITE FIELD, Memu Meadows is now a home to six structures designed by students. The effects of these “next-generation sustainable houses” will continue to be verified.
|
Accompanying Material |
||||||||
|
-- INFINITE FIELD designed by The Danish Royal Academy of Fine Arts (Denmark) |
||||||||
|
Supervisor: |
Anders Brix, Professor | |||||||
|
Students: |
Kazumasa Takada/Bas Spaanderman | |||||||
| Scarlett Emma Hessian/Jesse Thomas | ||||||||
| Benjamin Hock Yuu Tan/Konstantinos Fetsis | ||||||||
|
Design Supervisor: Kengo Kuma & Associates |
Structural Engineer: Oak Structural Design |
|
|
General Contractor: Takahashi Construction Company |
Building Area: 21.3m2 |
|
|
Construction Cost: Approx. 15 million yen |
||
|
Construction Period: August 2016 - October 2016 |
||
[Features]
-
Seasonal Transformation
INFINITE FIELD was imagined as a permeable experience, one where users are able to dictate their conditions, while engaging with the natural environment surrounding them. During the winter months it is from this elevated vantage point that users are aligned with an infinite sea of snow, and are treated to overlook the landscape from the warmth of the nest. In the summer heat the platform transforms into a place for rest and quiet reflection, looking out to a field of wild grasses, trees and bright blue skies. This 360-degree timber base is a contemplative oasis providing panoramic views of the natural surrounding. -
Spatial Tactility
INFINITE FIELD is an architecture of change and graduation, allowing users to experience and enjoy the shifting environment in comfort, while simultaneously enhancing our human connection with nature. A set of soft, permeable membranes made of varied textiles invites nature in and allows the design to move and breathe with the seasons. As you transition across the platform users can operate the membranes, moving them to add or remove barriers between the environment and themselves. These layers are an expanded threshold, an envelope inviting nature in while allowing a tactile interaction with the architecture. -
Material
Dwelling
The fabric architecture imparts a whole new perspective to familiar scenes. Silk fabric blades hang from the draped inner membrane disrupting heat and air flow. Users are able to visually perceive the gentle winds and air that flow through the dwelling as these fabric blades gently sway and flutter in the breeze. The project’s textiles are chosen with consideration of the various environmental properties, while their layered design provides adaptable thermal zones for user’s personal comfort.
-- Overview of Facility
Name:
Memu Meadows
Location:
158-1 Memu, Taiki-cho, Hiro-gun, Obihiro, Hokkaido
Owner:
LIXIL Foundation 2-1-1 Ojima, Koto-ku, Tokyo, 136-8535
Site
area:
App. 184,000 square meters
Main facilities:
Experimental
house “Même”, “Mock-up of Multiple floor Bamboo House”, “A recipe to
live”, “BARN HOUSE”, “HORIZON HOUSE”, “NEST WE GROW”, “INVERTED HOUSE”,
Multipurpose Facility, Conference Pavilion, Residence 1L and 1R
(accommodation for researchers), two log houses (accommodation for
researchers), fitness center, restaurant, Administration Wing, etc.
Official
website:
http://www.lixiljsfound.com/
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027007034/en/
Contact:
LIXIL Foundation
Kenji Iida, +81-3-5626-1008
2-1-1, Oshima,
Koto-ku, Tokyo 136-8535
Fax: +81-3-5626-1033
LIXIL Foundation
website: http://www.lixiljsfound.com/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
